Mapping a New Blueprint of Multimodal Immunotherapy Against Prostate Cancer: Breakthroughs, Barriers, and Bold Frontiers
The FASEB Journal · 2025
DOI: 10.1096/fj.202501308rr ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FASEB Journal, 2025. Verfasst von Yiting Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Immunotherapy, Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 138 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), Shenzhen Science and Technology Program, China Postdoctoral Science Foundation (China Postdoctoral Foundation Project).
Abstract (Originalsprache)
Immunotherapies have achieved remarkable success in treating various malignant tumors in recent years; however, their application in prostate cancer remains in the early stages of development. This is mainly because the disease has low immunogenicity, and its complex immune microenvironment limits the efficacy of single immunotherapy. Researchers are increasingly exploring novel immunotherapy strategies for this disease. Key approaches include immune checkpoint inhibitors (ICIs), which restore T cell function and enhance cytotoxic T lymphocyte (CTL) activity; cell therapies that target tumor‐associated antigens; cancer vaccines that stimulate immune responses against prostate cancer; and bispecific antibodies (BsAbs) that link tumor cells and T cells to promote tumor eradication. Combination therapies integrating immunotherapy with conventional treatments such as chemotherapy, androgen deprivation therapy (ADT), and radiotherapy further show potential to overcome prostate cancer's immunosuppressive microenvironment. This review discusses the current immunotherapy strategies for prostate cancer, highlights recent advancements, and explores the challenges and future directions in improving clinical outcomes for patients with this disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong, China.
ORCID-Profile: Yupeng Guan, Jun Pang
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- Shenzhen Science and Technology Program
- China Postdoctoral Science Foundation (China Postdoctoral Foundation Project)
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Cao, F., Huang, M., Teng, Q., Guan, Y., & Pang, J. (2025). Mapping a New Blueprint of Multimodal Immunotherapy Against Prostate Cancer: Breakthroughs, Barriers, and Bold Frontiers. The FASEB Journal. https://doi.org/10.1096/fj.202501308rr
Vancouver
Wang Y, Cao F, Huang M, Teng Q, Guan Y, Pang J. Mapping a New Blueprint of Multimodal Immunotherapy Against Prostate Cancer: Breakthroughs, Barriers, and Bold Frontiers. The FASEB Journal. 2025. doi:10.1096/fj.202501308rr
BibTeX
@article{Wang2025,
author = {Wang, Yiting and Cao, Fei and Huang, Mengjun and Teng, Qiliang and Guan, Yupeng and Pang, Jun},
title = {Mapping a New Blueprint of Multimodal Immunotherapy Against Prostate Cancer: Breakthroughs, Barriers, and Bold Frontiers},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202501308rr}
}
EUVIMED